Sample-to-Answer, Point-of-Care HPV DNA Test Feasible
Medically reviewed by Drugs.com.
By Elana Gotkine HealthDay Reporter
TUESDAY, June 27, 2023 -- A sample-to-answer, point-of-care human papillomavirus (HPV) DNA test is feasible and can be performed by minimally trained personnel, according to a study published online June 21 in Science Translational Medicine.
Kathryn A. Kundrod, Ph.D., from Rice University in Houston, and colleagues developed a prototype, sample-to-answer, point-of-care test for HPV16 and HPV18 DNA, relying on isothermal DNA amplification and lateral flow detection. All test components were integrated into a low-cost, manufacturable platform, and performance of the test was assessed with synthetic samples, provider-collected clinical samples in a high-resource setting in the United States, and self-collected samples from a low-resource setting in Mozambique.
The researchers found that the clinically relevant limit of detection was 1,000 HPV16 or HPV18 DNA copies per test. Six user steps were required for the test, and results were yielded in 45 minutes. The test can be performed using a benchtop instrument and minicentrifuge by personnel with minimal training. The projected costs were less than $5 per test and less than $1,000 for instrumentation.
"By demonstrating an effective solution to integrate sample preparation, isothermal amplification, and lateral flow detection that is appropriate for use in resource-limited settings, this work represents a major step toward a cervical cancer screening test that could be translated to clinical use in resource-limited settings and implemented at scale," the authors write.
Two authors disclosed ties to the biopharmaceutical industry.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted June 2023
Read this next
Quality Improvement Initiative Boosts Early HPV Vaccine Rates
THURSDAY, May 16, 2024 -- A multipronged primary care quality improvement initiative increases early human papillomavirus (HPV) vaccine initiation across racial/ethnic...
AACR: At-Home HPV Testing Boosts Cervical Cancer Screening Participation
FRIDAY, April 12, 2024 -- Mailed at-home self-sampling for human papillomavirus (HPV) testing increases cervical cancer screening participation in underscreened...
Disparities Seen in HPV Vaccine Uptake Among U.S. Adults
FRIDAY, March 29, 2024 -- There are sociodemographic disparities in human papillomavirus (HPV) vaccine uptake among 27- to 45-year-olds, according to a study published online...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.